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Volume overload in the dialysis patient is easy to
recognize when it presents itself emergently as short-
ness of breath. However, overt signs and symptoms
of heart failure such as an elevated jugular venous
pressure, displaced cardiac apex, third or fourth left
ventricular heart sounds, hepatomegaly, and edema
are often a late manifestation of volume overload.
More often, volume excess is covert. In this review,
I will discuss hypertension as a manifestation of
volume overload.
Elevated blood pressure documented between
dialysis treatments is an early manifestation of vol-
ume overload. Increase in volume results in an
increase in cardiac output. This increase in cardiac
output culminates in increased systemic vascular
resistance and consequently hypertension. The prev-
alence of hypertension, among 369 chronic HD
patients defined by either an 44-hour interdialytic
ambulatory BP of 135/85 mmHg or more or the
prescription of any antihypertensive agent, was 86%
(1). Although hypertension was being treated with
antihypertensive drugs in 89%, it was adequately
controlled only in 38%.
Among patients who have essential hypertension
with kidney disease, we commonly accept diuretic
responsive hypertension to be due to excess volume.
We do not require manifestations of volume excess
such as pedal edema, elevated jugular venous pres-
sure, displaced cardiac apex or other signs of vol-
ume overload before diagnosing volume-responsive
hypertension. Similarly, among hypertensive dialysis
patients we should not require overt signs of vol-
ume overload to diagnose volume-responsive hyper-
tension. Studies suggest that the presence or
absence of edema, which is often taken to be as a
reliable sign of volume overload, has no predictive
value in separating the responders from nonre-
sponders with dry-weight reduction (2). Perhaps the
best evidence for hypertension being a manifesta-
tion of volume excess comes from the dry-weight
reduction in hypertensive dialysis patients (DRIP)
trial (2).
In this randomized controlled trial dry-weight
was probed without changing dialysis time (2). This
study tested the hypothesis that hypertension
among HD patients who do not manifest overt
signs of volume overload is mediated by excess vol-
ume; accordingly, patients with obvious volume
overload were excluded. In this trial, 50 patients
were randomized to a control group and 100
patients randomized to ultrafiltration group and all
underwent interdialytic ambulatory blood pressure
monitoring three times (at baseline, 4 weeks, and
8 weeks). Despite stable concurrent use of 2.7 anti-
hypertensive drugs, in the ultrafiltration group, the
ambulatory BP was reduced within 4 weeks by
11/6 mmHg (2) After correcting for the placebo
effect seen in the control group ambulatory BP
reduction in the ultrafiltration group remained sig-
nificant at 7/3 mmHg. This antihypertensive effect
was sustained for 8 weeks of observation. Despite
provoking occasional uncomfortable intradialytic
symptoms, the quality of life was not impaired with
reducing dry weight. Often overlooked is the fact
that in this trial, 10% of the patients in the control
group developed accelerated hypertension (defined
as BP ≥175/105 mmHg by interdialytic ambulatory
monitoring). This study strongly supports the
hypothesis that, hypertension is a manifestation of
volume excess among HD patients. Furthermore,
lack of attention to dry-weight can result is severe
elevations in interdialytic blood pressure in one of
ten patients.
In clinical practice, hypertension is perhaps best
detected by performing blood pressure monitoring
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at home over a few days (3,4). Home BP monitor-
ing is recommended by several societies (5,6) but is
especially valuable in diagnosing and managing
hypertension among patients on dialysis (7). Home
BP correlates more closely with ambulatory BP than
does predialysis or postdialysis BP recordings (8). It
can track changes in BP evoked by reduction in
dry-weight and is much more reproducible from one
week to the next compared to predialysis or postdi-
alysis BP recordings (9). Home BP is superior to
measurements made in the dialysis unit (even using
recommended techniques) in predicting the presence
of target organ damage (echocardiographic left
ventricular hypertrophy) (10,11) and long-term
outcomes such as cardiovascular events (12) or mor-
tality (12–15). A randomized trial suggests that
among long-term dialysis patients, home BP guided
antihypertensive therapy can better achieve hyper-
tension control at 6 months than antihypertensive
therapy guided by predialysis BP (16). Another trial
randomized 17 HD patients to usual care and 17 to
home BP monitoring; average weekly systolic BP
improved only in the home BP group (17). These
data support the use of home BP measurement to
diagnose and treat hypertension among patients on
HD.
Among HD patients, the timing and frequency of
home BP monitoring is of particular importance.
Home BP increases on average at a rate of 4 mmHg
every 10 hours elapsed after dialysis (18). Therefore,
measurement soon after dialysis or just before dialy-
sis will underestimate or overestimate the burden of
hypertension. Therefore, it is important to measure
BP at various intervals following dialysis. Measure-
ments made twice daily (on waking up in the
morning and just before going to sleep) following a
mid-week dialysis for 4 days (19) are practical ways
to follow patients over time.
Another indicator of volume overload in a dialy-
sis patient is the use of multiple antihypertensive
drugs. If blood pressure remains uncontrolled after
full doses of three antihypertensive drugs, it is quite
likely that volume excess is present. The knee-jerk
response to elevated blood pressure in a dialysis
patient of increasing the number of antihypertensive
drugs is likely to fail if volume overload is not ade-
quately addressed. In a cross-sectional study of 369
patients at one center, the independent determinants
of poor control were the use of antihypertensive
drugs and an expanded extracellular volume state
(1). In longitudinal follow up, if patients were vol-
ume overloaded, nearly 80% became hypertensive
when medications were withdrawn. Paradoxically,
the more medications the patients received, the
more likely they were to be hypertensive.
In conclusion, volume excess often manifests
as hypertension in dialysis patients and volume
reduction is a practical way to lower BP among
such patients.
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